• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pacira Pharm Inc (NQ: PCRX )

    15.47 -0.06 (-0.39%)
    Streaming Delayed Price Updated: 9:36 AM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,804
    Open 15.37
    Bid (Size) 15.38 (2)
    Ask (Size) 15.50 (2)
    Prev. Close 15.53
    Today's Range 15.30 - 15.70
    52wk Range 11.16 - 35.95
    Shares Outstanding 44,454,792
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire

    Performance

    YTD
    -51.66%
    -51.66%
    1 Month
    +1.91%
    +1.91%
    3 Month
    -28.58%
    -28.58%
    6 Month
    -46.67%
    -46.67%
    1 Year
    -47.07%
    -47.07%

    More News

    Read More
    Expert Ratings For Pacira BioSciences
    Via Benzinga
    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Pacira BioSciences
    Via GlobeNewswire
    Where Pacira BioSciences Stands With Analysts
    Via Benzinga
    Expert Ratings For Pacira BioSciences
    Via Benzinga
    NASDAQ:PCRX: good value for what you're paying.
    Via Chartmill
    Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
    From Pacira BioSciences
    Via GlobeNewswire
    NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    NASDAQ:PCRX, an undervalued stock with good fundamentals.
    Via Chartmill
    PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Pacira BioSciences Reports Second Quarter 2024 Financial Results
    From Pacira BioSciences
    Via GlobeNewswire
    3 Biotech Stocks to Buy on the Dip: July 2024
    Via InvestorPlace
    Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
    From Pacira BioSciences
    Via GlobeNewswire
    In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
    From Pacira BioSciences
    Via GlobeNewswire
    Top 5 Health Care Stocks That May Explode In July
    Via Benzinga
    This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
    Via Benzinga
    Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
    Via Benzinga
    Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
    From Pacira BioSciences
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.